Treating

MyeTxScheduler (MyeTx) is a free online tool that helps healthcare professionals create clear, adaptable myeloma treatment schedules to support patient understanding and medication management.

In the seventh co-partnered digital infosession from Myeloma UK and UKMS, chaired by Dr Jennifer Travers, clinicians discuss practical approaches to transplant and non-transplant decision making in myeloma, with a focus on shared decision making and real-world case discussion.

In the sixth co-partnered digital infosession from Myeloma UK and UKMS, held on 15 October 2025 and chaired by Dr Jennifer Travers, leading clinicians explored the ocular toxicities associated with belantamab mafodotin (Blenrep®). The session focused on recognising, monitoring and managing eye-related side effects to support safer and more effective treatment delivery.

This British Society of Haematology and UK Myeloma Society guideline on the management of relapsed and refractory myeloma was developed to support clinicians making treatment decisions after disease progression following at least one prior line of treatment.

This myeloma nurse guide on bispecific antibodies supports nurses caring for people with relapsed or refractory myeloma. It explains treatment mechanisms, step-up dosing and pre-medications, and offers clear guidance on monitoring and managing side effects including CRS, ICANS, infection risk, and gastrointestinal or skin toxicities.

In the fifth co-partnered digital infosession from Myeloma UK and UKMS, held on 26 March 2025 and chaired by Professor Guy Pratt, leading clinicians explored the pressing issue of frailty in myeloma patients. The session focused on effective strategies for assessing frailty risk and integrating these practices into everyday clinical care.

Discover the EMMBRAce Project – a UK-wide initiative supporting hospitals in delivering bispecific antibody therapies to multiple myeloma patients. Explore resources, guidance, and educational tools designed to help healthcare providers deliver these life-changing treatments locally.

The paper outlines a consensus approach to diagnosis, treatment and monitoring of MGRS, including guidance on the investigations required to confirm the condition, principles of supportive care, and haematological treatment strategies. It also highlights the need for ongoing multidisciplinary collaboration in managing this rare but clinically important disorder.

This guide provides nurses with expert insights on managing precursor conditions to myeloma, including MGUS, MGRS, and smouldering myeloma. It covers essential monitoring, risk assessment, and patient care strategies to support early detection and improve patient outcomes.

The fourth co-partnered digital infosession from Myeloma UK and UKMS, held on 16 October 2024 and hosted by Professor Gordon Cook, covers cutting-edge strategies for managing renal complications in myeloma, including myeloma cast nephropathy, paraprotein-related kidney disease, and comprehensive treatment and supportive care approaches.